M. J. Goodman

Publication List Details

Period

1966 - 1997

Number

25

Co-Authors

Ammonium inhibits processing and cytotoxicity of reovirus, a nonenveloped virus.

Maratos-Flier, E, Goodman, M J, Murray, A H, Kahn, C R

Successful viral infection involves a series of interactions between the virus and the host cell. The outcome of viral infection is, in fact, dependent on intact cellular function; it is required for...

Chronic disease, functional health status, and demographics: a multi-dimensional approach to risk adjustment.

Hornbrook, M C, Goodman, M J

OBJECTIVE. The goal of this study was to develop unbiased risk-assessment models to be used for paying health plans on the basis of enrollee health status and use propensity. We explored the risk...

The impact of increasing patient prescription drug cost sharing on therapeutic classes of drugs received and on the health status of elderly HMO members.

Johnson, R E, Goodman, M J, Hornbrook, M C, Eldredge, M B

OBJECTIVE: To assess the impact of increased prescription drug copayments on the therapeutic classes of drugs received and health status of the elderly. HYPOTHESES TESTED: Increased prescription drug...

Ammonium inhibits processing and cytotoxicity of reovirus, a nonenveloped virus.

Maratos-Flier, E, Goodman, M J, Murray, A H, Kahn, C R

Successful viral infection involves a series of interactions between the virus and the host cell. The outcome of viral infection is, in fact, dependent on intact cellular function; it is required for...

Chronic disease, functional health status, and demographics: a multi-dimensional approach to risk adjustment.

Hornbrook, M C, Goodman, M J

OBJECTIVE. The goal of this study was to develop unbiased risk-assessment models to be used for paying health plans on the basis of enrollee health status and use propensity. We explored the risk...

The impact of increasing patient prescription drug cost sharing on therapeutic classes of drugs received and on the health status of elderly HMO members.

Johnson, R E, Goodman, M J, Hornbrook, M C, Eldredge, M B

OBJECTIVE: To assess the impact of increased prescription drug copayments on the therapeutic classes of drugs received and health status of the elderly. HYPOTHESES TESTED: Increased prescription drug...

Why do patients with ulcerative colitis relapse?

Riley, S A, Mani, V, Goodman, M J, Lucas, S

To determine the factors responsible for ulcerative colitis relapse a cohort of 92 patients (18 to 78 years, 50 men) with clinically inactive disease have been followed for over 48 weeks. At 12...

Microscopic activity in ulcerative colitis: what does it mean?

Riley, S A, Mani, V, Goodman, M J, Dutt, S, Herd, M E

To determine the prognostic importance of microscopic rectal inflammation we followed up 82 patients (aged 21 to 78 years, 44 men) with chronic quiescent ulcerative colitis over 12 months. At trial...

Glucosamine synthetase activity of the colonic mucosa in ulcerative colitis and Crohn's disease.

Goodman, M J, Kent, P W, Truelove, S C

Glucosamine synthetase is the first enzyme in glycoprotein biosynthesis, catalysing the formation of glucosamine-6-phosphate, from which N-acetylglucosamine is formed. The levels of this enzyme in...

Glucosamine synthetase activity of the colonic mucosa in membranous colitis.

Goodman, M J, Kent, P W, Truelove, S C

Glucosamine synthetase, the first enzyme in glycoprotein synthesis, has been measured in serial rectal biopsies in four patients with membranous colitis. In two of the patients the levels of the...

Sulphasalazine induced seminal abnormalities in ulcerative colitis: results of mesalazine substitution.

Riley, S A, Lecarpentier, J, Mani, V, Goodman, M J, Mandal, B K, Turnberg, L A

Seminal abnormalities are commonly found during sulphasalazine treatment. Although these changes appear reversible after drug withdrawal this may result in colitis relapse. Animal studies suggest...

Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse.

Riley, S A, Mani, V, Goodman, M J, Herd, M E, Dutt, S, Turnberg, L A

Oral formulations of 5-aminosalicylic acid (mesalazine) appear less toxic than sulphasalazine. We have therefore compared sulphasalazine, low dose mesalazine and high dose mesalazine in the treatment...